Welcome to our dedicated page for CG Oncology SEC filings (Ticker: CGON), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CG Oncology, Inc. filings document the public-company record of a late-stage clinical biopharmaceutical issuer focused on cretostimogene grenadenorepvec for non-muscle invasive bladder cancer. Recent Form 8-K reports disclose financial results, Regulation FD materials, clinical-program updates, FDA-related communications, executive appointments, board changes and other material events.
The company's SEC record also includes proxy disclosures on board structure, compensation and stockholder matters, along with registration and prospectus materials related to common-stock offerings under an open market sale agreement. These filings describe CG Oncology's Nasdaq-listed common stock, capital-raising activity, governance framework, clinical development priorities and risk-related disclosure context.
CG Oncology is amending its existing at-the-market common stock program with Jefferies to increase the aggregate offering capacity by an additional $500.0 million, bringing the total potential offering size to $1,050.0 million of common stock under its Form S-3ASR shelf. The company has already sold 10,800,525 shares for gross proceeds of approximately $550.0 million under the sales agreement.
Sales may be made from time to time as an “at the market offering” through Jefferies, which will earn up to 3.0% of gross proceeds. An illustrative scenario assumes selling 6,904,170 shares at $72.42 per share, implying immediate dilution of $55.92 per share to new investors versus an as adjusted net tangible book value of $16.50 per share. Net tangible book value as of March 31 2026 was $1,080.9 million, or $12.28 per share.
CGON insider Ambaw Bellete filed a notice to sell up to 25,000 shares of common stock through Morgan Stanley Smith Barney LLC Executive Financial Services, with an aggregate market value of $1,837,500.00, on or after August 5, 2026 on NASDAQ. These shares are tied to a stock option exercise paid in cash on the same date.
The filing also lists recent sales of CGON common stock during the prior three months by Ambaw Bellete, including 52,438 shares for $3,816,007.65 on July 15, 2026, and additional transactions on July 23, 27, 28, and 29, 2026 with share amounts ranging from 4,303 to 50,000 shares.
CGON filed a notice of proposed sales of common stock. The filing lists 4,303 common shares to be sold through Morgan Stanley Smith Barney LLC Executive Financial Services, tied to a stock option exercise with an intended sale date of July 29, 2026 on NASDAQ.
Over the prior three months, Ambaw Bellete is reported as having sold several large common stock blocks: 50,000 shares on July 15, 23, and 27, 2026 and 52,438 shares on July 15, 2026, with disclosed gross proceeds amounts for each sale.
Ambaw Bellete filed a Form 144 indicating an intention to sell 50,000 shares of common stock of CGON through Morgan Stanley Smith Barney LLC Executive Financial Services on NASDAQ on or after July 28, 2026, in connection with a stock option exercise. The notice also lists prior sales over the past three months totaling more than 150,000 shares of common stock.
BlackRock, Inc. reports its beneficial ownership of common stock of CG ONCOLOGY INC on an amended Schedule 13G. BlackRock discloses beneficial ownership of 6,023,696 shares of common stock, representing 6.8% of the outstanding class as of the reporting date.
BlackRock has sole voting power over 5,914,671 shares and sole dispositive power over all 6,023,696 shares, with no shared voting or dispositive power. The filing notes that various persons have rights to receive dividends or sale proceeds from these shares, but no individual person holds more than five percent of CG ONCOLOGY INC’s total outstanding common shares.
An affiliate of CGON, identified as Ambaw Bellete, filed a notice to sell 50,000 shares of common stock, to be delivered through a stock option exercise on 07/27/2026, with Morgan Stanley Smith Barney LLC Executive Financial Services as broker.
The planned 50,000-share sale is valued at $3,627,995.00. The filer also reports prior sales during the past three months, including 50,000 shares for $3,588,620.00 on 07/23/2026 and 52,438 shares for $3,816,007.65 on 07/15/2026.
CGON filed to allow the sale of common stock by an affiliate. The filing lists a proposed sale of 50,000 shares of common stock through Morgan Stanley Smith Barney LLC on NASDAQ on July 23, 2026, with an aggregate market value of $3,588,620.00. The shares are to be sold for cash and were acquired from the issuer on July 23, 2026 through a stock option exercise. In the preceding three months, a holder identified as Ambaw Bellete sold 52,438 common shares on July 15, 2026 for total proceeds of $3,816,007.65.
CG Oncology, Inc. director Leonard E. Post exercised stock options for 1,000 shares of Common Stock at $0.60 per share and on July 15, 2026 sold 1,000 shares at $71.17 per share. The sale was effected under a Rule 10b5-1 trading plan adopted on March 5, 2026. Following these transactions, he held no Common Stock directly and 105,077 fully vested Director Stock Options.
CG Oncology, Inc. director James Mulay exercised a fully vested director stock option to acquire 24,165 shares of common stock at an exercise price of $26.63 per share. He then sold 24,165 shares in an open-market transaction at a weighted average price of $75.16 per share.
The sales were executed under a Rule 10b5-1 trading plan adopted on March 27, 2026, with individual sale prices ranging from $74.98 to $75.79. After these transactions, this report shows 0 common shares and 0 related director stock options remaining in the reported accounts.